



P/1259-637

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Date: November 1, 2004

Fernand LABRIE

Confirmation No.: 3989

Serial No.: 10/052,803

Group Art Unit: 1617

Filed: November 7, 2001

Examiner: S. Jiang

For: SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION WITH
ESTROGENS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Submitted herewith is a copy of art together with a form listing the same for the convenience of the Examiner.

It is believed that no fee is due at this stage of the proceedings. However, in the event a fee is due and not enclosed, or if any additional fee due during the pendency of this application is not paid, the Patent and Trademark Office is authorized to charge the underpayment to Deposit Account No. 15-0700.

EXPRESS MAIL CERTIFICATE

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail to Addressee (mail label # EV 342536226US) in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, Alexandria, VA 22313-1450, on November 1, 2004

Dorothy Jenkins

Name of Person Mailing Correspondence


Dorothy Jenkins
Signature

November 1, 2004

Date of Signature

WOG:mjb

Respectfully submitted,


William O. Gray, III


Registration No.: 30,944

OSTROLENK, FABER, GERB & SOFFEN, LLP

1180 Avenue of the Americas

New York, New York 10036-8403

Telephone: (212) 382-0700

APPLICANT'S ART CITATION (Use several sheets if necessary)		Application 10/052,803				OFGS File No. P/1259-637					
		Applicant Fernand LABRIE									
		Filing Date November 7, 2001				Group Art Unit 1617					
U.S. PATENT DOCUMENTS											
Examiner Initial	Document Number						Date	Name	Class	Sub- class	Filing Date If Appropriate
											
	Document Number						Date	Country	Class	Sub- class	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
1.	K. Abrahamsson et al., "Transient reduction of human left ventricular mass in carnitine depletion induced by antibiotics containing pivalic acid," Br. Heart J. 74:656-659, 1995.										
2.	K. Abrahamsson et al., "Pivalic acid-induced carnitine deficiency and physical exercise in humans," Metabolism 45(12):1501-1507, 1996.										
3.	K. Abrahamsson et al., "Effect of short-term treatment with pivalic acid containing antibiotics on serum carnitine concentration - a risk irrespective of age, biochemical and molecular medicine," 55(1):77-79, 1995.										
4.	I. Ito et al., "Alteration of ammonia and carnitine levels in short-term treatment with pivalic acid-containing prodrug," Tohoku J. of Exp. Med. 175(1):43-53, 1995.										
5.	K. Abrahamsson et al., "Impaired ketogenesis in carnitine depletion caused by short-term administration of pivalic acid prodrug," Biochem. Med. and Met. Biol. 52(1):18-21, 1994.										
6.	Y. Toyonaga et al., "Effect of cefditoren povoxil on carnitine metabolism in pediatric patients," Japan Journal of Antibiotics 46(10):926-937, 1993.										
7.	M. Tanimura et al., "Carnitine status and safety after administration of S-1108, a new oral cephem, to patients," Antimicrobial Agents and Chemotherapy 37(5):1043-1049, 1993.										
8.	Couillard, S.; Labrie, C.; Gauthier, S.; Labrie, F., Abstract, <i>Maturitas</i> , (1997), Vol. 27, No. SUPPL., pp. 80, Title: "Inhibitory Effect of a new Non-Steroidal Pure Antiestrogen (EM-800) in Combination with DHEA on Human ZR-75-1 Breast Tumors in Nude Mice".										
Examiner						Date Considered					
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.											